Tirzepatide and semaglutide are the two most prescribed GLP-1 class medications for weight management in 2026. Both are available as compounded medications through licensed telehealth providers. Both require a physician prescription. And both have strong clinical evidence behind them. The question most patients and providers face is: which one is right for this specific patient at this specific point in their treatment?

This guide covers the clinical data, mechanism differences, cost comparison, and practical considerations for choosing between the two — based on peer-reviewed evidence including the landmark SURMOUNT-5 trial published in the New England Journal of Medicine in 2025.

How They Work: Mechanism Differences

Semaglutide — GLP-1 Receptor Agonist

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the GLP-1 hormone your body naturally produces after eating — signaling fullness to the brain, slowing gastric emptying, and helping regulate blood sugar. Administered via once-weekly subcutaneous injection, semaglutide produces consistent appetite suppression and gradual weight reduction.

The STEP 1 trial (New England Journal of Medicine, 2021) established semaglutide’s clinical profile in a large-scale, randomized controlled trial setting. Semaglutide has a robust, well-characterized evidence base accumulated over several years of clinical use.

Tirzepatide — Dual GLP-1/GIP Receptor Agonist

Tirzepatide activates two hormone receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-agonist mechanism produces synergistic effects on appetite control and metabolic function that are more pronounced than GLP-1 activation alone. The combined stimulation influences appetite-regulating neurons more broadly than single-pathway agents.

The SURMOUNT-5 trial (New England Journal of Medicine, 2025) provided the first large-scale, head-to-head randomized controlled comparison of tirzepatide vs. semaglutide in patients with obesity. It is the most clinically authoritative data available for comparing these two medications directly.

What the SURMOUNT-5 Trial Found (NEJM 2025)

The SURMOUNT-5 trial was a pivotal study — the first major head-to-head randomized controlled trial comparing tirzepatide and semaglutide at their respective highest doses in patients with obesity. Key findings from SURMOUNT-5 (NEJM, 2025):

• Tirzepatide produced greater mean body weight reduction than semaglutide at the maximum doses studied
• A higher proportion of tirzepatide-treated patients achieved clinically meaningful weight reduction thresholds compared to semaglutide-treated patients
• Both medications demonstrated tolerability profiles consistent with earlier individual trials

Individual results vary significantly based on starting weight, dosing, adherence, diet, physical activity, and individual health factors. The SURMOUNT-5 trial reflects population-level outcomes, not guaranteed individual results.

Clinical Comparison: Tirzepatide vs. Semaglutide

Cost Comparison: CoraDoc™ Pricing for Both Medications

Through CoraDoc™, both compounded semaglutide and compounded tirzepatide are available at transparent, all-inclusive pricing with no subscription:

All programs include free provider visit, free 2-day shipping via DIRX pharmacy, and free supplies. One payment — no subscription, no auto-renew.

Which Should You Choose? Practical Guidance

Consider Starting with Semaglutide If:

• You want the lower-cost option ($99/mo vs. $149/mo for the 6-month program)
• You prefer the medication with a longer cumulative evidence base
• Your licensed provider recommends it based on your individual health profile
• You want to start conservatively and reassess after a full program

Consider Tirzepatide If:

• Your provider determines based on your health profile that the dual-agonist mechanism is appropriate
• You have reviewed the SURMOUNT-5 data with your provider and discussed expected outcomes
• Budget allows for the higher monthly rate ($149/mo vs. $99/mo)

The decision should always be made with a licensed physician based on your individual health history, current medications, and treatment goals. CoraDoc™’s board-certified physicians review each patient intake individually before issuing any prescription.

Side Effects: What to Expect

Both medications share a similar GI side effect profile, particularly in the first 4–8 weeks:

• Nausea — most common; often improves as dose stabilizes
• Constipation or diarrhea — typically transient
• Reduced appetite — expected and clinically desirable
• Fatigue — often resolves in early weeks

Eating smaller meals, staying hydrated, and avoiding high-fat foods in the early weeks helps minimize GI symptoms. If side effects are persistent or severe, contact your CoraDoc™ care team at 855-983-5336 or careteam@coradoc.com to discuss dose adjustment.

Frequently Asked Questions

Is tirzepatide always more effective than semaglutide?

The SURMOUNT-5 trial (NEJM, 2025) showed greater mean weight reduction with tirzepatide at maximum doses studied. However, individual results vary based on many factors. Some patients respond well to semaglutide and may not see meaningfully different outcomes with tirzepatide. Your licensed provider can help determine which is more appropriate based on your specific profile.

Can I switch from semaglutide to tirzepatide?

Transitions between GLP-1 medications are medically managed decisions. If you are considering switching, discuss this with your CoraDoc™ provider — they can review your current progress and advise on dosing for a transition if appropriate.

Are the compounded versions of these medications equivalent to brand-name products?

Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished drug products and are not equivalent to brand-name medications in the regulatory sense. They are prepared by licensed 503A compounding pharmacies under applicable regulations. Eligibility and safety determinations are made by licensed physicians.